Vivanza Biosciences Ltd

Vivanza Biosciences has faced notable volatility, hitting a new 52-week low and experiencing a significant decline over the past nine days. The stock is trading below all major moving averages, reflecting ongoing challenges, while the broader miscellaneous sector has also encountered difficulties this year.

Vivanza Biosciences has faced significant stock volatility, recently hitting a 52-week low and declining 28.29% over the past eight days. The company’s stock is trading below key moving averages, and it has experienced a 74.61% drop over the past year, contrasting with broader market trends.

Vivanza Biosciences has hit a new 52-week low, continuing a downward trend over the past week with a cumulative loss of nearly 29%. The company has significantly underperformed its sector and experienced a 75% decline over the past year, trading below its moving averages across multiple time frames.

Vivanza Biosciences has reached a new 52-week low, experiencing a significant decline over the past six days and a staggering drop over the past year. The company's performance has lagged behind its sector, and it is currently trading below its moving averages across multiple time frames.

Vivanza Biosciences has faced significant market challenges, hitting a new 52-week low and experiencing a 14.8% decline over the past four days. The company has seen a 67.61% drop in its stock price over the past year, underperforming its sector and trading below key moving averages.

Vivanza Biosciences has faced notable volatility, hitting a new 52-week low and experiencing a 9.54% decline over the past three days. The company has struggled over the past year, with a 65.11% decrease, significantly underperforming compared to the Sensex, which has gained 9.01%.

Vivanza Biosciences has faced notable volatility, hitting a new 52-week low and experiencing a 9.54% decline over the past three days. The company has struggled over the past year, with a 65.11% decrease, significantly underperforming compared to the Sensex, which has gained 9.01%.

Vivanza Biosciences has announced its financial results for the quarter ending January 2025, reflecting a negative performance for Q3 FY24-25. Despite this, the company's evaluation score has improved from -10 to -8 over the past three months, indicating a potential shift in its financial health assessment.

Vivanza Biosciences has faced significant volatility, hitting a new 52-week low and continuing a downward trend. The company's stock has declined 62.45% over the past year, underperforming the Sensex. It is currently trading below its moving averages, highlighting ongoing challenges in the microcap sector.

Vivanza Biosciences has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company is trading below its moving averages, indicating a sustained downward trend. The broader miscellaneous sector is also experiencing challenges, contributing to a tough market environment.

Vivanza Biosciences has recently undergone a revision in its score, reflecting ongoing challenges in the market. The stock has reached a new 52-week low and has significantly underperformed compared to its sector. Additionally, it has been added to MarketsMOJO's list, highlighting its current struggles.

Vivanza Biosciences has recently undergone a revision in its score, reflecting ongoing challenges in its market performance. The stock has been added to MarketsMOJO's list, highlighting concerns as it continues to trade below key moving averages and has significantly underperformed its sector over the past year.

Vivanza Biosciences has recently experienced a revision in its score by MarketsMOJO, reflecting a challenging market position. The stock has reached a 52-week low and has underperformed significantly compared to the sector and the Sensex. Investors are advised to exercise caution given the current trends and performance indicators.

Vivanza Biosciences, a microcap company in the miscellaneous industry, has hit a 52-week low on October 23, 2024. The stock is currently trading at Rs.3.36, below its moving averages and has seen a decline of 67.26% in the past year. Investors should carefully consider the company's performance and consult with a financial advisor before investing.

Vivanza Biosciences, a microcap company in the miscellaneous industry, has hit a 52-week low on October 22, 2024, with a stock price of Rs.3.52. The company's performance has been lower than its moving averages and the overall market, indicating significant underperformance. Investors should carefully consider their options due to the company's small market capitalization.

Vivanza Biosci. has reported a negative net profit margin and a debt-free capital structure in the last quarter. The company's low cash balance may affect its short-term obligations. Despite this, Vivanza remains committed to its mission and continues to invest in research and development. Investors should conduct thorough research before making any investment decisions.

The stock has recently hit a 52-week low of Rs 3.64 and is currently trading below its moving averages, indicating a downward trend. In the past year, the stock has underperformed the sector and the overall market, with a significant decline of -66.25%.

Vivanza Biosciences, a microcap company in the miscellaneous industry, has hit a 52-week low on October 3rd, 2024, with a current stock price of Rs.3.64. The stock has been given a Strong Sell rating by MarketsMOJO and has underperformed the sector by -0.45%. It has also been on a downward trend for the past five days and is trading below all its moving averages, indicating a bearish sentiment among investors. Over the past year, the company has seen a decline of -65.43%, highlighting its underperformance compared to the overall market. This article provides a factual overview of Vivanza Biosciences' recent stock performance and does not include any external data or recommendations. Investors should conduct their own research before making any investment decisions.